TY - JOUR
T1 - Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes
AU - Hirose, Hiroshi
AU - Kawai, Toshihide
AU - Yamamoto, Yukihiro
AU - Taniyama, Matsuo
AU - Tomita, Motowo
AU - Matsubara, Koichi
AU - Okazaki, Yasunori
AU - Ishii, Tatsuya
AU - Oguma, Yuko
AU - Takei, Izumi
AU - Saruta, Takao
N1 - Funding Information:
From the Department of Internal Medicine, Keio University School of Medicine, Tokyo; 3rd Department of Internal Medicine and Department of Physiological Chemistry, School of Pharmaceutical Sciences, Showa University School of Medicine, Tokyo; and the Chugai Diagnostics Science Co, Tokyo, Japan. Submitted April 26, 2001; accepted September 10, 2001. Supported in part by research grants (to H.H.) from Keio University, Tokyo, Japan. Presented in part at the 61st Annual Meeting of the American Diabetes Association, Philadelphia, PA, June 22-26, 2001. Address reprint requests to Hiroshi Hirose, MD, Department of Internal Medicine, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan. Copyright © 2002 by W.B. Saunders Company 0026-0495/02/5103-0009$35.00/0 doi:10.1053/meta.2002.30506
PY - 2002
Y1 - 2002
N2 - The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P < .01 for all), and HbA1c (6.7 ± 0.8 to 6.1% ± 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P < .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.
AB - The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P < .01 for all), and HbA1c (6.7 ± 0.8 to 6.1% ± 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P < .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.
UR - http://www.scopus.com/inward/record.url?scp=0036125944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036125944&partnerID=8YFLogxK
U2 - 10.1053/meta.2002.30506
DO - 10.1053/meta.2002.30506
M3 - Article
C2 - 11887166
AN - SCOPUS:0036125944
SN - 0026-0495
VL - 51
SP - 314
EP - 317
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 3
ER -
